- Home
- PRE vs TCRX Comparison
PRE vs TCRX Comparison
Compare PRE & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRE
- TCRX
- Stock Information
- Founded
- PRE 2014
- TCRX 2018
- Country
- PRE Hong Kong
- TCRX United States
- Employees
- PRE N/A
- TCRX N/A
- Industry
- PRE Biotechnology: Laboratory Analytical Instruments
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- PRE Industrials
- TCRX Health Care
- Exchange
- PRE Nasdaq
- TCRX Nasdaq
- Market Cap
- PRE 105.4M
- TCRX 90.5M
- IPO Year
- PRE N/A
- TCRX 2021
- Fundamental
- Price
- PRE $8.33
- TCRX $1.80
- Analyst Decision
- PRE Buy
- TCRX Strong Buy
- Analyst Count
- PRE 1
- TCRX 6
- Target Price
- PRE $9.00
- TCRX $9.50
- AVG Volume (30 Days)
- PRE 43.8K
- TCRX 834.6K
- Earning Date
- PRE 06-17-2025
- TCRX 05-06-2025
- Dividend Yield
- PRE N/A
- TCRX N/A
- EPS Growth
- PRE N/A
- TCRX N/A
- EPS
- PRE N/A
- TCRX N/A
- Revenue
- PRE $30,621,000.00
- TCRX $4,421,000.00
- Revenue This Year
- PRE $148.70
- TCRX $151.70
- Revenue Next Year
- PRE $82.89
- TCRX N/A
- P/E Ratio
- PRE N/A
- TCRX N/A
- Revenue Growth
- PRE 40.83
- TCRX N/A
- 52 Week Low
- PRE $3.10
- TCRX $1.02
- 52 Week High
- PRE $11.99
- TCRX $9.29
- Technical
- Relative Strength Index (RSI)
- PRE 55.29
- TCRX 65.78
- Support Level
- PRE $5.58
- TCRX $1.39
- Resistance Level
- PRE $9.51
- TCRX $1.81
- Average True Range (ATR)
- PRE 1.30
- TCRX 0.13
- MACD
- PRE -0.18
- TCRX 0.05
- Stochastic Oscillator
- PRE 42.82
- TCRX 96.24
About PRE Prenetics Global Limited
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.